These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22839720)

  • 1. [Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine].
    Gogolashvili NG
    Kardiologiia; 2012; 52(7):84-92. PubMed ID: 22839720
    [No Abstract]   [Full Text] [Related]  

  • 2. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
    Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
    Mori Y; Kuriyama G; Tanaka T; Tajima N
    Endocrine; 2009 Dec; 36(3):412-8. PubMed ID: 19834827
    [No Abstract]   [Full Text] [Related]  

  • 4. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
    Pasanen MK; Fredrikson H; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2007 Dec; 82(6):726-33. PubMed ID: 17473846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin wars: emphasis on potency vs event reduction and safety?
    Lavie CJ; Milani RV; O'Keefe JH
    Mayo Clin Proc; 2007 May; 82(5):539-42. PubMed ID: 17493417
    [No Abstract]   [Full Text] [Related]  

  • 6. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
    Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW
    Eur J Prev Cardiol; 2013 Dec; 20(6):1080-7. PubMed ID: 23644489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High coronary plaque load: a heavy burden.
    de Graaf MA; Jukema JW
    Eur Heart J; 2013 Nov; 34(41):3168-70. PubMed ID: 23966308
    [No Abstract]   [Full Text] [Related]  

  • 8. Intensive lipid intervention in the post-ENHANCE era.
    O'Keefe JH; Bybee KA; Lavie CJ
    Mayo Clin Proc; 2008 Aug; 83(8):867-9. PubMed ID: 18674470
    [No Abstract]   [Full Text] [Related]  

  • 9. New statins and new doses of older statins.
    Stein EA
    Curr Atheroscler Rep; 2001 Jan; 3(1):14-8. PubMed ID: 11123843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
    Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
    Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
    Pham PA; la Porte CJ; Lee LS; van Heeswijk R; Sabo JP; Elgadi MM; Piliero PJ; Barditch-Crovo P; Fuchs E; Flexner C; Cameron DW
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4385-92. PubMed ID: 19667285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First head-to-head study comparing rosuvastatin and atorvastatin effects on the treatment of atherosclerosis.
    Cardiovasc J Afr; 2008; 19(1):60. PubMed ID: 18320096
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
    Folse H; Sternhufvud C; Andy Schuetz C; Rengarajan B; Gandhi S
    Clin Ther; 2014 Jan; 36(1):58-69. PubMed ID: 24417785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
    Leiter LA; Rosenson RS; Stein E; Reckless JP; Schulte KL; Schleman M; Miller P; Palmer M; Sosef F;
    Atherosclerosis; 2007 Oct; 194(2):e154-64. PubMed ID: 17229426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin-induced arrest in progression of renal disease.
    Vidt DG; Cressman MD; Harris S; Pears JS; Hutchinson HG
    Cardiology; 2004; 102(1):52-60. PubMed ID: 15073451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin in patients with elevated C-reactive protein.
    Fugh-Berman A
    N Engl J Med; 2009 Mar; 360(10):1038-9; author reply 1041-2. PubMed ID: 19271272
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
    Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
    Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
    Bays HE; Averna M; Majul C; Muller-Wieland D; De Pellegrin A; Giezek H; Lee R; Lowe RS; Brudi P; Triscari J; Farnier M
    Am J Cardiol; 2013 Dec; 112(12):1885-95. PubMed ID: 24063830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosuvastatin and atorvastatin on renal function: meta-analysis.
    Wu Y; Wang Y; An C; Dong Z; Liu H; Zhang Y; Zhang M; An F
    Circ J; 2012; 76(5):1259-66. PubMed ID: 22382383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.